动物造模,三阴乳腺癌NOD/SCID小鼠模型 z-bio 2021-05-24 480

　　Objective: To establish a NOD/SCID mouse model with human immunological characteristics and observe its immune response to triple-negative breast cancer.

　　Method: Screen 24 NOD/SCID mice without immune leakage and divide them into 4 groups. In the immune reconstitution group, 250 mg/kg cyclophosphamide (CTX) was injected intraperitoneally 3 days ago, and then healthy human peripheral blood mononuclear cells were injected. Cells (PBMC) At the same time, human triple-negative breast cancer cells MDA-MB-231 were subcutaneously injected into the back, only CTX and PBMC were injected into the immune group, and only MDA-injected into the oncogene group. MB-231; untreated blank control group. Regularly observe the biological and immunological characteristics of each group of mice.

　　Result: The tumor incubation period (10-12d) of the immune tumor-bearing group is longer than the tumor incubation period (8-10d) of the tumor-bearing group alone, and the tumor growth rate is slower. At the 5th week, they were 1244.82±792.82 mm3 and 4308.77 mm3, respectively (P\u003c0.01), and the survival time was improved (P\u003c0.01). In the second week, human IgG in the peripheral blood of immune-reconstituted mice was detected and gradually increased. Compared with mice without immune reconstitution, this is statistically significant (P\u003c0.01). In the 2nd week, the percentage of CD3+ cells in the peripheral blood gradually decreased, but it was also detectable in the 9th week. In the 9th week, the proportion of CD3 + T cells in mouse spleen cells was higher, 55.3% (immune cancer group) and 52.7% (simple cancer group), respectively. The spleen index of mice in the immune tumor group was 9.64 mg/g, which was significantly higher than 3.82±0.31 mg/g in the immune group and 1.51±0.14 mg/g in the blank control group.

　　Conclusion: We have successfully constructed a stable NOD/SCID mouse model with human immunological characteristics and observed an immune response against triple-negative breast cancer. This can provide an ideal animal model for triple-negative breast cancer immunotherapy research.